Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET

Schizophrenia Research

Volumn 108, Issue 1-3, 2009, Pages 78-84

  Nozaki, Shoko ^a,b   Kato, Motoichiro ^b   Takano, Harumasa ^a,b   Ito, Hiroshi ^a   Takahashi, Hidehiko ^a   Arakawa, Ryosuke ^a   Okumura, Masaki ^a   Fujimura, Yota ^a   Matsumoto, Ryohei ^a   Ota, Miho ^a   Takano, Akihiro ^a   Otsuka, Akihiko ^d   Yasuno, Fumihiko ^a   Okubo, Yoshiro ^c   Kashima, Haruo ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d Otsuka Clinic   (Japan)

Author keywords

11C DOPA; Dopamine synthesis; PANSS; Positron emission tomography (PET); Schizophrenia

Indexed keywords

CARBON 11; DOPAMINE; LEVODOPA;

ADULT; ARTICLE; CAUDATE NUCLEUS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; MENTAL DISEASE; OCCIPITAL CORTEX; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; SUBICULUM; TEMPORAL CORTEX; THALAMUS;

ADULT; BRAIN MAPPING; CARBON RADIOISOTOPES; CHI-SQUARE DISTRIBUTION; DOPAMINE; DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 60249091351     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.11.006     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV (1994), American Psychiatric Association, Washington, DC, USA
2. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349 (1997) 1730-1734
3. Braff D.L., Swerdlow N.R., and Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 156 (1999) 596-602
4. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2569-2574
5. Buchsbaum M.S., Someya T., Teng C.Y., Abel L., Chin S., Najafi A., Haier R.J., Wu J., and Bunney Jr. W.E. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am. J. Psychiatry 153 (1996) 191-199
6. 18F]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 85 (2006) 232-244
7. Carlsson A., Waters N., Waters S., and Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brain Res. Brain Res. Rev. 31 (2000) 342-349
8. Clark C., Kopala L., Li D.K., and Hurwitz T. Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can. J. Psychiatry 46 (2001) 340-345
9. Clinton S.M., and Meador-Woodruff J.H. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr. Res. 69 (2004) 237-253
10. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., Artiges E., Feline A., Syrota A., and Martinot J.L. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr. Res. 23 (1997) 167-174
11. Dhawan V., Ishikawa T., Patlak C., Chaly T., Robeson W., Belakhlef A., Margouleff C., Mandel F., and Eidelberg D. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J. Nucl. Med. 37 (1996) 209-216
12. Elkashef A.M., Doudet D., Bryant T., Cohen R.M., Li S.H., and Wyatt R.J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res. 100 (2000) 1-11
13. 11C]raclopride. Arch. Gen. Psychiatry 47 (1990) 213-219
14. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders: SCID-1 Clinician Version (1997), American Psychiatric Publishing, Inc., Arlington, USA
15. Gefvert O., Lindström L.H., Waters N., Waters S., Carlsson A., and Tedroff J. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scand. J. Psychol. 44 (2003) 289-292
16. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 257 (1982) 237-274
17. Gründer G., Vernaleken I., Muller M.J., Davids E., Heydari N., Buchholz H.G., Bartenstein P., Munk O.L., Stoeter P., Wong D.F., Gjedde A., and Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (2003) 787-794
18. Hazlett E.A., Buchsbaum M.S., Byne W., Wei T.C., Spiegel-Cohen J., Geneve C., Kinderlehrer R., Haznedar M.M., Shihabuddin L., and Siever L.J. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatry 156 (1999) 1190-1199
19. Hazlett E.A., Buchsbaum M.S., Kemether E., Bloom R., Platholi J., Brickman A.M., Shihabuddin L., Tang C., and Byne W. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am. J. Psychiatry 161 (2004) 305-314
20. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela O., Ruotsalainen U., and Salokangas R. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346 (1995) 1130-1131
21. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Eronen E., Ruotsalainen U., and Salokangas R.K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 35 (1999) 41-50
22. Igarashi Y., Hayashi N., Yamashina M., Otsuka N., Kuroki N., Anzai N., and Kazamatsuri H. Interrater reliability of the Japanese version of the positive and negative syndrome scale and the appraisal of its training effect. Psychiatry Clin. Neurosci. 52 (1998) 467-470
23. 11C]DOPA. Nucl. Med. Commun. 27 (2006) 723-731
24. Kim J.J., Mohamed S., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. Am. J. Psychiatry 157 (2000) 542-548
25. Kircher T.T., Liddle P.F., Brammer M.J., Williams S.C., Murray R.M., and McGuire P.K. Reversed lateralization of temporal activation during speech production in thought disordered patients with schizophrenia. Psychol. Med. 32 (2002) 439-449
26. 18F]fluorodopa/positron emission tomography study. J. Neurosci. 27 (2007) 8080-8087
27. Laakso A., Vilkman H., Alakare B., Haaparanta M., Bergman J., Solin O., Peurasaari J., Rakkolainen V., Syvalahti E., and Hietala J. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am. J. Psychiatry 157 (2000) 269-271
28. Laakso A., Vilkman H., Bergman J., Haaparanta M., Solin O., Syvalahti E., Salokangas R.K., and Hietala J. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol. Psychiatry 52 (2002) 759-763
29. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
30. 123I]beta-CIT. Biol. Psychiatry 47 (2000) 371-379
31. 11C) DOPA and PET. Biol. Psychiatry 46 (1999) 681-688
32. Mai J., Assheuer J., and Paxinos G. Atlas of the Human Brain (1997), Academic Press, New York
33. 18F]fluorodopa study. Arch. Gen. Psychiatry 61 (2004) 134-142
34. McGraw K.O., and Wong S.P. Forming inferences about some intraclass correlation coefficients. Psychol. Methods 1 (1996) 30-46
35. 3H]L-dopa in rats. Biochem. Pharmacol. 39 (1990) 1853-1860
36. Mitelman S.A., Byne W., Kemether E.M., Hazlett E.A., and Buchsbaum M.S. Metabolic disconnection between the mediodorsal nucleus of the thalamus and cortical Brodmann's areas of the left hemisphere in schizophrenia. Am. J. Psychiatry 162 (2005) 1733-1735
37. 11C]N-methylspiperone. Psychiatry Res. 61 (1995) 67-83
38. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia 9 (1971) 97-113
39. 11C]DOPA. Life Sci. 79 (2006) 730-736
40. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 13 (1990) 254-258
41. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5 (1985) 584-590
42. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., Bachneff S., Cumming P., Diksic M., Dyve S.E., Etienne P., Evans A.C., Lal S., Shevell M., Savard G., Wong D.F., Chouinard G., and Gjedde A. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 11651-11654
43. Resnick S.M., Gur R.E., Alavi A., Gur R.C., and Reivich M. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res. 24 (1988) 1-11
44. Salem J.E., and Kring A.M. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin. Psychol. Rev. 18 (1998) 795-819
45. Salokangas R.K., Vilkman H., Ilonen T., Taiminen T., Bergman J., Haaparanta M., Solin O., Alanen A., Syvalahti E., and Hietala J. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am. J. Psychiatry 157 (2000) 632-634
46. 99mTc]TRODAT-1. J. Psychopharmacol. 19 (2005) 488-493
47. Shergill S.S., Brammer M.J., Williams S.C., Murray R.M., and McGuire P.K. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch. Gen. Psychiatry 57 (2000) 1033-1038
48. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 59 (2002) 25-30
49. 2 receptors in schizophrenia. Biol. Psychiatry 59 (2006) 919-928
50. 11C]FLB 457. Int. J. Neuropsychopharmacol. 6 (2003) 361-370
51. 2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 148 (2006) 165-173
52. 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system. J. Cereb. Blood Flow Metab. 19 (1999) 1142-1149
53. 3 receptor density and distribution in drug-naïve schizophrenic patients. Mol. Psychiatry 8 (2003) 453-455
54. 18F]6-fluoro-3-O-methyl-L-dopa in the human brain. J. Cereb. Blood Flow Metab. 14 (1994) 664-670
55. 2 dopamine receptors in drug-naïve schizophrenics. Science 234 (1986) 1558-1563
56. Woodruff P.W., Wright I.C., Bullmore E.T., Brammer M., Howard R.J., Williams S.C., Shapleske J., Rossell S., David A.S., McGuire P.K., and Murray R.M. Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Am. J. Psychiatry 154 (1997) 1676-1682
57. 3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am. J. Psychiatry 161 (2004) 1496-1498
58. 2 receptor binding in subregions of the thalamus in schizophrenia. Am. J. Psychiatry 161 (2004) 1016-1022
59. Young K.A., Randall P.K., and Wilcox R.E. Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodents. Neuroreport 6 (1995) 2495-2499